Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink?

  • Erica Stringer-Reasor
  • Gini Fleming
  • Daliah Tsoref
  • Amit Oza


Chemotherapy has been the treatment for endometrial cancer over the last several decades. Recently targeted agents have been investigated in attempts to further individualize therapy. Perhaps, hormonal therapy can be seen as the first biological targeted agent followed by anti-VEGF agents and mTOR inhibitors. Chemotherapy continues to be the mainstay in the treatment of endometrial cancer despite the development of these novel agents. In the future, combining chemotherapy with targeted agents shows promise in improving progression-free survival in patients with endometrial cancer.


Hormonal Therapy Endometrial Cancer Endometrial Carcinoma mTOR Inhibitor Gynecologic Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Madison T, Schottenfeld D, James SA, Schwartz AG, Gruber SB. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health. 2004;94(12):2104–11. Epub 2004/12/01.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009;16(1):38–45. Epub 2008/12/17.PubMedGoogle Scholar
  3. 3.
    Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006;4(6):459–68. Epub 2006/09/20.PubMedGoogle Scholar
  4. 4.
    Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol. 2009;36(2):145–54. Epub 2009/04/01.PubMedCrossRefGoogle Scholar
  5. 5.
    Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 1994;12(7):1408–14. Epub 1994/07/01.PubMedGoogle Scholar
  6. 6.
    Pawinski A, Tumolo S, Hoesel G, Cervantes A, van Oosterom AT, Boes GH, et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC gynecological cancer cooperative group. Eur J Obstet Gynecol Reprod Biol. 1999;86(2):179–83. Epub 1999/10/06.PubMedCrossRefGoogle Scholar
  7. 7.
    Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2003;21(20):3808–13. Epub 2003/10/11.PubMedCrossRefGoogle Scholar
  8. 8.
    Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group. Ann Oncol. 2003;14(3):441–8. Epub 2003/02/25.PubMedCrossRefGoogle Scholar
  9. 9.
    Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(19):3902–8. Epub 2004/10/02.PubMedCrossRefGoogle Scholar
  10. 10.
    Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a gynecologic oncology group study. Ann Oncol. 2004;15(8):1173–8. Epub 2004/07/28.PubMedCrossRefGoogle Scholar
  11. 11.
    Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(11):2159–66. Epub 2004/06/01.PubMedCrossRefGoogle Scholar
  12. 12.
    Miller DS. Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study: SGO. 2012:abstract #1.Google Scholar
  13. 13.
    Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncology. 2006;101(1):158–67. Epub 2006/01/26.CrossRefGoogle Scholar
  14. 14.
    Vandenput I, Vergote I, Neven P, Amant F. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer. 2012;22(4):617–22. Epub 2012/03/20.PubMedCrossRefGoogle Scholar
  15. 15.
    Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011;121(1):118–21. Epub 2010/12/17.PubMedCrossRefGoogle Scholar
  16. 16.
    Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, et al. A phase II evaluation of pemetrexed (alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the gynecologic oncology. Gynecol Oncol. 2009;115(3):443–6. Epub 2009/10/07.PubMedCrossRefGoogle Scholar
  17. 17.
    Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P, Alvarez RD. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol. 2009;27(19):3104–8. Epub 2009/05/20.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2003;88(3):277–81. Epub 2003/03/22.PubMedCrossRefGoogle Scholar
  19. 19.
    Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2002;87(3):247–51. Epub 2002/12/07.PubMedCrossRefGoogle Scholar
  20. 20.
    Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist. 2010;15(10):1026–33. Epub 2010/10/12.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008;63(1):157–66. Epub 2008/03/19.PubMedCrossRefGoogle Scholar
  22. 22.
    McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncology. 2007;106(1):16–22. Epub 2007/06/19.CrossRefGoogle Scholar
  23. 23.
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7. Epub 1983/02/01.PubMedCrossRefGoogle Scholar
  24. 24.
    Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83 Suppl 1:79–118. Epub 2004/02/07.PubMedCrossRefGoogle Scholar
  25. 25.
    Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012;13(1):1–13. Epub 2011/12/27.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2007;106(2):325–33. Epub 2007/05/29.PubMedCrossRefGoogle Scholar
  27. 27.
    Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 1996;14(2):357–61. Epub 1996/02/01.PubMedGoogle Scholar
  28. 28.
    Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose–response study by the gynecologic oncology group. J Clin Oncol. 1999;17(6):1736–44. Epub 1999/11/24.PubMedGoogle Scholar
  29. 29.
    Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001;19(2):364–7. Epub 2001/02/24.PubMedGoogle Scholar
  30. 30.
    Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(1):4–9. Epub 2004/01/31.PubMedCrossRefGoogle Scholar
  31. 31.
    Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(1):10–4. Epub 2004/01/31.PubMedCrossRefGoogle Scholar
  32. 32.
    Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001;24(1):43–6. Epub 2001/03/10.PubMedCrossRefGoogle Scholar
  33. 33.
    McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 2003;90(1):64–9. Epub 2003/06/25.PubMedCrossRefGoogle Scholar
  34. 34.
    Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. 1997;64(1):126–9. Epub 1997/01/01.PubMedCrossRefGoogle Scholar
  35. 35.
    Lhomme C, Vennin P, Callet N, Lesimple T, Achard JL, Chauvergne J, et al. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol. 1999;75(2):187–93. Epub 1999/10/20.PubMedCrossRefGoogle Scholar
  36. 36.
    Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF. Goserelin acetate as treatment for recurrent endometrial carcinoma: a gynecologic oncology group study. Am J Clin Oncol. 2002;25(6):557–60. Epub 2002/12/13.PubMedCrossRefGoogle Scholar
  37. 37.
    Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2000;78(2):212–6. Epub 2000/08/06.PubMedCrossRefGoogle Scholar
  38. 38.
    Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14(4):650–8. Epub 2004/08/12.PubMedCrossRefGoogle Scholar
  39. 39.
    Kleine W, Maier T, Geyer H, Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 1990;38(1):59–65. Epub 1990/07/01.PubMedCrossRefGoogle Scholar
  40. 40.
    Lentz SS. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol. 1994;21(1):100–6. Epub 1994/02/01.PubMedGoogle Scholar
  41. 41.
    Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–78. Epub 2007/04/20.PubMedCrossRefGoogle Scholar
  42. 42.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–37. Epub 1994/04/06.PubMedCrossRefGoogle Scholar
  43. 43.
    Burnett AF, Bahador A, Amezcua C. Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. Gynecol Oncol. 2004;94(3):832–4. Epub 2004/09/08.PubMedCrossRefGoogle Scholar
  44. 44.
    Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol. 1994;55(1):144–8. Epub 1994/10/01.PubMedCrossRefGoogle Scholar
  45. 45.
    Aea O. A randomized Phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma. J Clin Oncol. 2011;29:abstract #5009.Google Scholar
  46. 46.
    Gu C, Zhang Z, Yu Y, Liu Y, Zhao F, Yin L, et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci. 2011;102(3):557–64. Epub 2011/01/06.PubMedCrossRefGoogle Scholar
  47. 47.
    Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. Epub 2011/12/14.PubMedCrossRefGoogle Scholar
  48. 48.
    Bea T. TAMRAD: a Gineco Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). Cancer Res. 2010;70(24 Suppl):1–490. Abstract # S1–6.Google Scholar
  49. 49.
    Bhattacharvva GS, Biswas J, Singh JK, Singh M, Govindbabu K, Ranade AA, et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. Eur J Cancer. 2011;47 Suppl 2:9.CrossRefGoogle Scholar
  50. 50.
    Slomovitz BM, Brown J, Johnston TA, Mura D, Levenback C, Wolf J, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2011;29:abstract #5012.Google Scholar
  51. 51.
    Fleming GF, Filiaci VL, Hanjani P, Burke JJ, Davidson SA, Leslie K, et al. Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. J Clin Oncol. 2011;29:abstract #5014.Google Scholar
  52. 52.
    Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010(12):CD007926. Epub 2010/12/15.Google Scholar
  53. 53.
    Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–45. Epub 2004/08/18.PubMedCrossRefGoogle Scholar
  54. 54.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81. Epub 2007/06/01.PubMedCrossRefGoogle Scholar
  55. 55.
    Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol. 2011;29(24):3278–85. Epub 2011/07/27.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Einstein MH, Wenham RM, Morgan R, Cristea MC, Strevel EL, Amit M, Oza AM, et al. Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer. J Clin Oncol. 2012;30(15s):abstract #5025.Google Scholar
  57. 57.
    Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, Elit L, et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol. 2012;23(1):238–44. Epub 2011/03/31.PubMedCrossRefGoogle Scholar
  58. 58.
    Colombo N, McMeekin S, Schwartz P, Kostka J, Sessa C, Gehrig P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2007;25(18S):abstract #5516.Google Scholar
  59. 59.
    Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–9. Epub 2010/08/04.PubMedCrossRefGoogle Scholar
  60. 60.
    Mackay H, Eisenhauser E, Kamel-Reid S, et al. Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC). J Clin Oncol. 2012;31(15 Suppl):abstract #5010.Google Scholar
  61. 61.
    Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075–83. Epub 2010/01/21.PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Dobrzycka B, Terlikowski SJ, Kwiatkowski M, Garbowicz M, Kinalski M, Chyczewski L. Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer. Ginekol Pol. 2010;81(6):422–5. Epub 2010/08/11.PubMedGoogle Scholar
  63. 63.
    Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 2007;27(5B):3525–8. Epub 2007/11/02.PubMedGoogle Scholar
  64. 64.
    Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol. 2011;29(16):2259–65. Epub 2011/05/04.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Correa R, Mackay H, Hirte HW, Morgan R, Welch S, Fleming GF, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma; a trial of the Princess Margaret Hospital, the University of Chicago, and California Cancer phase II Consortia. J Clin Oncol. 2010;28, No 15_(May 20 suppl):abstract #5038.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Erica Stringer-Reasor
    • 1
  • Gini Fleming
    • 1
  • Daliah Tsoref
    • 2
  • Amit Oza
    • 3
  1. 1.Internal Medicine, Section: Hematology/OncologyUniversity of ChicagoChicagoUSA
  2. 2.Medical OncologyPrincess Margaret HospitalTorontoCanada
  3. 3.Department of MedicinePrincess Margaret Cancer CentreTorontoCanada

Personalised recommendations